Evidence map›Paper›PMID 28401143›Full record

ArticleCMAJ open

Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study.

Joice Rocha, Armen G Aprikian, Marie Vanhuyse, Fabio L Cury, Jason Hu, Noémie Prévost, Alice Dragomir

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CMAJ open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Joice RochaDivision of Urology (Rocha, Aprikian, Hu, Prévost, Dragomir), Department of Surgery, McGill University; Research Institute of the McGill University Health Centre (Rocha, Hu, Prévost, Dragomir); Division of Medical Oncology (Vanhuyse) and Division of Radiation Oncology (Cury), Department of Oncology, McGill University; McGill University Health Centre (Aprikian, Vanhuyse, Cury), Montréal, Que.
Armen G AprikianDivision of Urology (Rocha, Aprikian, Hu, Prévost, Dragomir), Department of Surgery, McGill University; Research Institute of the McGill University Health Centre (Rocha, Hu, Prévost, Dragomir); Division of Medical Oncology (Vanhuyse) and Division of Radiation Oncology (Cury), Department of Oncology, McGill University; McGill University Health Centre (Aprikian, Vanhuyse, Cury), Montréal, Que.
Marie VanhuyseDivision of Urology (Rocha, Aprikian, Hu, Prévost, Dragomir), Department of Surgery, McGill University; Research Institute of the McGill University Health Centre (Rocha, Hu, Prévost, Dragomir); Division of Medical Oncology (Vanhuyse) and Division of Radiation Oncology (Cury), Department of Oncology, McGill University; McGill University Health Centre (Aprikian, Vanhuyse, Cury), Montréal, Que.
Fabio L CuryDivision of Urology (Rocha, Aprikian, Hu, Prévost, Dragomir), Department of Surgery, McGill University; Research Institute of the McGill University Health Centre (Rocha, Hu, Prévost, Dragomir); Division of Medical Oncology (Vanhuyse) and Division of Radiation Oncology (Cury), Department of Oncology, McGill University; McGill University Health Centre (Aprikian, Vanhuyse, Cury), Montréal, Que.
Jason HuDivision of Urology (Rocha, Aprikian, Hu, Prévost, Dragomir), Department of Surgery, McGill University; Research Institute of the McGill University Health Centre (Rocha, Hu, Prévost, Dragomir); Division of Medical Oncology (Vanhuyse) and Division of Radiation Oncology (Cury), Department of Oncology, McGill University; McGill University Health Centre (Aprikian, Vanhuyse, Cury), Montréal, Que.
Noémie PrévostDivision of Urology (Rocha, Aprikian, Hu, Prévost, Dragomir), Department of Surgery, McGill University; Research Institute of the McGill University Health Centre (Rocha, Hu, Prévost, Dragomir); Division of Medical Oncology (Vanhuyse) and Division of Radiation Oncology (Cury), Department of Oncology, McGill University; McGill University Health Centre (Aprikian, Vanhuyse, Cury), Montréal, Que.
Alice DragomirDivision of Urology (Rocha, Aprikian, Hu, Prévost, Dragomir), Department of Surgery, McGill University; Research Institute of the McGill University Health Centre (Rocha, Hu, Prévost, Dragomir); Division of Medical Oncology (Vanhuyse) and Division of Radiation Oncology (Cury), Department of Oncology, McGill University; McGill University Health Centre (Aprikian, Vanhuyse, Cury), Montréal, Que.
McGill University · CAMcGill University Health Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbiraterone acetate was introduced in Quebec in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who had received chemotherapy with docetaxel. This study describes abiraterone use in the early postapproval period and its clinical effectiveness in Quebec, for both patients who had received docetaxel chemotherapy and those who could not receive docetaxel therapy owing to medical reasons.

methodsA retrospective cohort study was conducted using Quebec public health care administrative databases. Our cohort consisted of patients with mCRPC who received abiraterone between January 2012 and June 2013. Treatment groups were defined as patients who received abiraterone following docetaxel chemotherapy and those who received abiraterone without having had chemotherapy, under the "exception patient" measure. Study outcomes included overall survival, duration of abiraterone therapy and number of hospital days. Cox proportional hazard regression was used to estimate the effectiveness of abiraterone adjusted for several covariates.

resultsOur cohort consisted of 303 patients with mCRPC treated with abiraterone (99 after chemotherapy and 204 as exception patients). The median age at initiation of abiraterone therapy was 75.0 for the postchemotherapy group and 80.0 for the exception patient group. The corresponding median survival values were 12 and 14 months (log-rank test

interpretationThe effectiveness of abiraterone in older patients who were ineligible for chemotherapy was similar to that of patients with prior docetaxel exposure. Overall, the real-world survival benefits of abiraterone were similar to those in the COU-AA-301 trial.

Identifiers

PMID28401143
PMCPMC5378527
OpenAlexW2598538935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.